TY - JOUR
T1 - Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer
AU - Carr, Silvana
AU - Allison, Kim J.
AU - Van De Velde, Lee Ann
AU - Zhang, Kelly
AU - English, Elizabeth Y.
AU - Iverson, Amy
AU - Daw, Najat C.
AU - Howard, Scott C.
AU - Navid, Fariba
AU - Rodriguez-Galindo, Carlos
AU - Yang, Jie
AU - Adderson, Elisabeth E.
AU - Mccullers, Jonathan A.
AU - Flynn, Patricia M.
N1 - Funding Information:
Financial support. This work was supported by the American Lebanese Syrian Associated Charities; and by a grant from MedImmune (to S. C.) for conduct and analysis of the study. MedImmune was not involved in the conception, design, conduct, or interpretation of this study.
PY - 2011/11/15
Y1 - 2011/11/15
N2 - (See the editorial commentary by Halasa, on pages 1471-4.)Background.The safety and immunogenicity of live, attenuated influenza vaccine (LAIV) has not been compared to that of the standard trivalent inactivated vaccine (TIV) in children with cancer.Methods.Randomized study of LAIV versus TIV in children with cancer, age 2-21 years, vaccinated according to recommendations based on age and prior vaccination. Data on reactogenicity and other adverse events and blood and nasal swab samples were obtained following vaccination.Results.Fifty- five eligible subjects (mean age, 10.4 years) received vaccine (28 LAIV/27 TIV). Both vaccines were well tolerated. Rhinorrhea reported within 10 days of vaccination was similar in both groups (36% LAIV vs 33% TIV, P >. 999). Ten LAIV recipients shed virus; the latest viral shedding was detected 7 days after vaccination. Immunogenicity data were available for 52 subjects, or 26 in each group. TIV induced significantly higher postvaccination geometric mean titers against influenza A viruses (P <. 001), greater seroprotection against influenza A/H1N1 (P =. 01), and greater seroconversion against A/H3N2 (P =. 004), compared with LAIV. No differences after vaccination were observed against influenza B viruses.Conclusions.As expected, serum antibody response against influenza A strains were greater with TIV than with LAIV in children with cancer. Both vaccines were well tolerated, and prolonged viral shedding after LAIV was not detected.
AB - (See the editorial commentary by Halasa, on pages 1471-4.)Background.The safety and immunogenicity of live, attenuated influenza vaccine (LAIV) has not been compared to that of the standard trivalent inactivated vaccine (TIV) in children with cancer.Methods.Randomized study of LAIV versus TIV in children with cancer, age 2-21 years, vaccinated according to recommendations based on age and prior vaccination. Data on reactogenicity and other adverse events and blood and nasal swab samples were obtained following vaccination.Results.Fifty- five eligible subjects (mean age, 10.4 years) received vaccine (28 LAIV/27 TIV). Both vaccines were well tolerated. Rhinorrhea reported within 10 days of vaccination was similar in both groups (36% LAIV vs 33% TIV, P >. 999). Ten LAIV recipients shed virus; the latest viral shedding was detected 7 days after vaccination. Immunogenicity data were available for 52 subjects, or 26 in each group. TIV induced significantly higher postvaccination geometric mean titers against influenza A viruses (P <. 001), greater seroprotection against influenza A/H1N1 (P =. 01), and greater seroconversion against A/H3N2 (P =. 004), compared with LAIV. No differences after vaccination were observed against influenza B viruses.Conclusions.As expected, serum antibody response against influenza A strains were greater with TIV than with LAIV in children with cancer. Both vaccines were well tolerated, and prolonged viral shedding after LAIV was not detected.
UR - http://www.scopus.com/inward/record.url?scp=80054734187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054734187&partnerID=8YFLogxK
U2 - 10.1093/infdis/jir561
DO - 10.1093/infdis/jir561
M3 - Article
C2 - 21949042
AN - SCOPUS:80054734187
SN - 0022-1899
VL - 204
SP - 1475
EP - 1482
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 10
ER -